Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CEA/anti-CD3 bispecific antibody BA1202

A bispecific antibody targeting both the tumor-associated antigen (TAA) carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5; CEA) and CD3 antigen found on T lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CEA/anti-CD3 bispecific antibody BA1202 targets and binds to both CEA expressed on tumor cells and CD3 on cytotoxic T lymphocytes (CTLs). This activates and redirects CTLs to CEA-expressing tumor cells, which results in the CTL-mediated cell death of CEA-expressing tumor cells. CEA is overexpressed by a variety of cancer cell types and plays a key role in cell migration, cell invasion, and cell adhesion.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-CD3/anti-CEA bispecific antibody BA1202
anti-CEA/CD3 bispecific antibody BA1202
anti-CEACAM5/anti-CD3 bispecific antibody BA1202
CEA x CD3 bispecific antibody BA1202
Code name:BA 1202
BA-1202
BA1202
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search